An in vivo model for testing inhibition of arginine-induced insulin and glucagon release by somatostatin analogs

A. Gordin, C. Meyers, A. Arimura, D. H. Coy, Andrew V Schally

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

An animal model for testing the in vivo potency of somatostatin analogs in inhibiting the release of insulin and glucagon is described. The secretion of these pancreatic hormones was stimulated in rat by infusion of arginine. The plasma insulin level increased almost to a maximum after an infusion of 10 min, while plasma glucagon rose more slowly, reaching its maximum only after a 30 min infusion. Concomitant infusion of graded doses of somatostatin (2.5, 10, 40 and 160 mug/100 g BW) for 30 min inhibited both insulin and glucagon release in a dose-dependent manner, enabling the authors to test somatostatin analogs for insulin and glucagon-suppressive activity in a semi-quantitative manner. Using this animal model, 3 analogs of somatostatin, [D-Cys 14], [Ala 2, D-Cys 14]- and [D-Trp 8, D-Cys 14] somatostatin were tested in a 4-point assay. They all showed dissociated activity in inhibiting the secretion of glucagon more than that of insulin.

Original languageEnglish
Pages (from-to)833-841
Number of pages9
JournalActa Endocrinologica
Volume86
Issue number4
StatePublished - Dec 1 1977
Externally publishedYes

Fingerprint

Somatostatin
Glucagon
Arginine
Insulin
Animal Models
Pancreatic Hormones

ASJC Scopus subject areas

  • Endocrinology

Cite this

An in vivo model for testing inhibition of arginine-induced insulin and glucagon release by somatostatin analogs. / Gordin, A.; Meyers, C.; Arimura, A.; Coy, D. H.; Schally, Andrew V.

In: Acta Endocrinologica, Vol. 86, No. 4, 01.12.1977, p. 833-841.

Research output: Contribution to journalArticle

@article{8d7ede4131da4f61aa4e1a20cc8fa91f,
title = "An in vivo model for testing inhibition of arginine-induced insulin and glucagon release by somatostatin analogs",
abstract = "An animal model for testing the in vivo potency of somatostatin analogs in inhibiting the release of insulin and glucagon is described. The secretion of these pancreatic hormones was stimulated in rat by infusion of arginine. The plasma insulin level increased almost to a maximum after an infusion of 10 min, while plasma glucagon rose more slowly, reaching its maximum only after a 30 min infusion. Concomitant infusion of graded doses of somatostatin (2.5, 10, 40 and 160 mug/100 g BW) for 30 min inhibited both insulin and glucagon release in a dose-dependent manner, enabling the authors to test somatostatin analogs for insulin and glucagon-suppressive activity in a semi-quantitative manner. Using this animal model, 3 analogs of somatostatin, [D-Cys 14], [Ala 2, D-Cys 14]- and [D-Trp 8, D-Cys 14] somatostatin were tested in a 4-point assay. They all showed dissociated activity in inhibiting the secretion of glucagon more than that of insulin.",
author = "A. Gordin and C. Meyers and A. Arimura and Coy, {D. H.} and Schally, {Andrew V}",
year = "1977",
month = "12",
day = "1",
language = "English",
volume = "86",
pages = "833--841",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "4",

}

TY - JOUR

T1 - An in vivo model for testing inhibition of arginine-induced insulin and glucagon release by somatostatin analogs

AU - Gordin, A.

AU - Meyers, C.

AU - Arimura, A.

AU - Coy, D. H.

AU - Schally, Andrew V

PY - 1977/12/1

Y1 - 1977/12/1

N2 - An animal model for testing the in vivo potency of somatostatin analogs in inhibiting the release of insulin and glucagon is described. The secretion of these pancreatic hormones was stimulated in rat by infusion of arginine. The plasma insulin level increased almost to a maximum after an infusion of 10 min, while plasma glucagon rose more slowly, reaching its maximum only after a 30 min infusion. Concomitant infusion of graded doses of somatostatin (2.5, 10, 40 and 160 mug/100 g BW) for 30 min inhibited both insulin and glucagon release in a dose-dependent manner, enabling the authors to test somatostatin analogs for insulin and glucagon-suppressive activity in a semi-quantitative manner. Using this animal model, 3 analogs of somatostatin, [D-Cys 14], [Ala 2, D-Cys 14]- and [D-Trp 8, D-Cys 14] somatostatin were tested in a 4-point assay. They all showed dissociated activity in inhibiting the secretion of glucagon more than that of insulin.

AB - An animal model for testing the in vivo potency of somatostatin analogs in inhibiting the release of insulin and glucagon is described. The secretion of these pancreatic hormones was stimulated in rat by infusion of arginine. The plasma insulin level increased almost to a maximum after an infusion of 10 min, while plasma glucagon rose more slowly, reaching its maximum only after a 30 min infusion. Concomitant infusion of graded doses of somatostatin (2.5, 10, 40 and 160 mug/100 g BW) for 30 min inhibited both insulin and glucagon release in a dose-dependent manner, enabling the authors to test somatostatin analogs for insulin and glucagon-suppressive activity in a semi-quantitative manner. Using this animal model, 3 analogs of somatostatin, [D-Cys 14], [Ala 2, D-Cys 14]- and [D-Trp 8, D-Cys 14] somatostatin were tested in a 4-point assay. They all showed dissociated activity in inhibiting the secretion of glucagon more than that of insulin.

UR - http://www.scopus.com/inward/record.url?scp=0017665696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017665696&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 833

EP - 841

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 4

ER -